NCT05828901View on ClinicalTrials.gov

Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Multiple Sclerosis
Interventions
OTHER

S1PR analysis on immune cells

S1P receptor 1 and 5 expression will be measured on immune cells

Trial Locations (1)

3010

RECRUITING

Neurology department, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER